AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bioengineer

Published November 14, 2026 · Updated November 15, 2026

Blood Plasma Markers Predict Effectiveness of Psilocybin and Ketamine for Depression

Read the full story at Bioengineer

Researchers at Neuroscience 2026 reported that blood plasma biomarkers can predict individual therapeutic responses to psilocybin and ketamine for.

Post on X

Share this story

Surfaced by this Google Alert

Ketamine